1161 results about "Degenerative disease" patented technology

The invention discloses application and a preparation method of exosome EGF-FGF-EXO containing double growth factors, the exosome EGF-FGF-EXO is uniform in particle size, high in loading efficiency and good in biological activity, the double growth factors comprise an epidermal growth factor EGF and a fibroblast growth factor FGF, and the epidermal growth factor EGF and the fibroblast growth factor FGF are added into the exosome EGF-FGF. The preparation method of the exosome EGF-FGF-EXO comprises preparation of an induced pluripotent stem cell (iPSC) exosome and loading of EGF-FGF, a recombinant epidermal growth factor (EGF) and a fibroblast growth factor (FGF) are loaded on the exosome from iPS-clone 12c, and the exosome product which has high biological activity and is used for treating nervous system diseases of neuroinflammation is prepared. The invention develops a brand new technical path for treatment of nervous system diseases, and in the fields of epilepsy, neurodegenerative diseases, brain injury and the like, the life quality of patients can be improved and important theoretical basis and technical support can be provided for precise medical treatment of nervous system diseases by precisely regulating and controlling neuroinflammation.

The invention discloses a retina thickness prediction method and system based on a multi-modal image, and the method and system achieve the effective estimation of the retina thickness under a low-cost condition through feature alignment and fusion modeling, and improve the basic screening and follow-up visit capability. According to the invention, through fusion of the multi-mode retina image data, the structure and function information of the optic nerve can be more comprehensively obtained, and the prediction accuracy of the thickness of the retina nerve fiber layer (RNFL) is improved. The OCT high-resolution hierarchical structure and the wide-view texture features of the eye fundus image are combined, so that anatomy and pathological states of optic nerves can be truly restored. The method can be used as an auxiliary method for early screening and early warning of optic neurodegenerative diseases such as glaucoma, and provides support for low-cost and high-efficiency primary screening and clinical auxiliary decision making.

The invention relates to an intervertebral disc degenerative change analysis system based on multi-dimensional information. The system comprises a data processing module, a modifiable factor processing module, a circular RNA data processing module, a biomarker processing module, an image processing module, a treatment information processing module, a diagnostic feature anchoring module, a model generation module and a change analysis module. Anchoring is carried out on circular RNA, biomarkers, treatment information and modifiable factors through image information to form an anchoring network, and a reliable and effective basis can be provided for disease course analysis through big data and a large number of research results, so that each doctor has a targeted expectation and understanding on the disease course of a patient in the diagnosis stage; the method has the advantages that an interventional therapy scheme can be arranged in advance or the condition of a patient can be observed in real time, research results can be collected and fed back in time through big data, the information utilization rate is increased, and an information dimension integration scheme for degenerative disease recognition is created, and the accuracy of recognition results is improved.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for treating Parkinson's disease and a preparation method thereof. The traditional Chinese medicine preparation for treating Parkinson's disease comprises the following raw materials in parts by weight: 20-30 parts of bischofia polycarpa, 17-25 parts of eucommia ulmoides, 12-16 parts of artemisia sphaerocephala, 10-15 parts of lycopodium clavatum, 8-13 parts of elm leaves, 7-14 parts of pericarpium citri reticulatae, 5-10 parts of semen cuscutae and 2-7 parts of liquorice. In the formula, monarch, minister, assistant and guide are reasonably matched, the curative effect is exact, and the effects of regulating qi and blood, nourishing liver, warming kidney, activating blood and dissipating blood stasis are achieved. The compound can effectively improve core symptoms of Parkinson's disease and delay disease progression, is expected to be further developed into clinical drugs for treatment of Parkinson's disease, and provides an innovative scheme for traditional Chinese medicine treatment of neurodegenerative diseases.

The invention provides application of an SARM1 enzyme activity inhibitor in treating neurodegenerative diseases or neurological diseases or symptoms. The invention particularly provides a compound as an SARM1 enzyme activity inhibitor and a pharmaceutical composition of the compound. # imgabs0 #

A bioenergy generator to increase the life force of a biological system is provided. The bioenergy generator includes fine pieces of natural stone, fine pieces of natural sand, fine pieces of metal, water and a supporting material operable to hold the natural sand, the natural stone, the metal, and the water together. Uses of the bioenergy generator are also provided, in particular, to treat a muscular degenerative disease and to improve genetic mutations.

The invention provides an application of a pentacyclic triterpenoid compound targeting hydroxyl steroid 17-beta dehydrogenase 4. The pentacyclic triterpenoid compound can effectively relieve or treat central nervous system diseases (inflammatory diseases), including central nervous system degenerative diseases or chronic central inflammatory diseases. The pentacyclic triterpenoid compound can maintain the structural stability or activity of hydroxysteroid 17-beta dehydrogenase and maintain the stability or activity of peroxisome, thereby relieving or treating central nervous inflammation. The pentacyclic triterpenoid compound can target hydroxysteroid 17-beta dehydrogenase 4, inhibit neuroglial cell excessive activation related neuroinflammation, relieve neuron damage or death speed and improve a central nervous system cell metabolism microenvironment.

The present disclosure, in part, provide compounds of Formula (I) that are VPS34 inhibitors, compositions, and methods of use thereof, such as in methods of treating cancer, diabetes, inflammatory diseases, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections:

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

The invention relates to the technical field of nervous system dysfunction, in particular to a nerve regulation and control system for degenerative disease treatment based on multi-modal physiological feedback, which comprises a central processing unit, an optical radiation applicator, a mechanical vibration applicator, an integrated biological signal sensing array and a man-machine interaction module, cooperative stimulation is applied by using a multispectral light source and a broadband vibrator, and multi-dimensional physiological signals such as heart rate variability, myoelectricity, galvanic skin and the like are monitored in real time through a sensor array. A multi-parameter adaptive control algorithm built in the central processing unit can dynamically and intelligently adjust stimulation parameters based on the feedback signals to form an accurate personalized treatment closed loop. Meanwhile, the safety monitoring module based on the biological thermal model ensures the safety boundary of the treatment process. According to the invention, intelligent, self-adaptive and non-invasive treatment of nerve dysfunction is realized.

The invention provides a fluorescent probe for detecting hydroxyl radicals as well as a preparation method and application thereof, and the preparation method comprises the following steps: (S10) synthesizing a first intermediate compound by taking 2, 3, 3-trimethyl-3H-indoline and methyl iodide as raw materials; (S20) synthesizing a second intermediate compound by taking phosphorus trichloride, cyclohexanone and anhydrous dimethylformamide as raw materials; (S30) mixing and reacting the first intermediate compound and the second intermediate compound to synthesize a compound IR780; and (S40) synthesizing OH-probe on the basis of the IR780. The prepared OH-probe has extremely high sensitivity and excellent selectivity on hydroxyl radicals, can be effectively used for monitoring and mapping the level of the hydroxyl radicals, and can be applied to detection of atherosclerosis, obesity, cancers, neurodegenerative diseases, inflammatory diseases and other free radical related diseases. Wide development prospects and practical application values are realized.

Disclosed herein are small molecule compounds, compositions, formulations, and methods of modulating gpl30. Compounds, compositions, and formulations described herein are capable of modulating pro-inflammatory, fibrotic and / or regenerative responses. The disclosure also provides methods for treating or ameliorating disease, disorders and conditions associated with gp130 activity, particularly those associated with inflammatory and degenerative disorders, or combination thereof.

The invention discloses a preparation method and application of a novel bird nest alkane diterpenoid compound, and relates to the technical field of medicinal chemistry. The invention aims to solve the problems that chemical synthesis needs harsh conditions and the cost is difficult to control when diterpenoid compounds are obtained in the prior art, and a large amount of resources are wasted and new molecules are difficult to obtain under conventional fermentation conditions. The prepared bird nest alkane type diterpene has dual functions of promoting neurite growth and nourishing neurons, is expected to be developed into a neuroprotective agent, and is used for treating neurodegenerative diseases and peripheral nerve injury diseases; meanwhile, the problems that in the prior art, when the compounds are obtained, conditions needed by chemical synthesis are harsh, the cost is difficult to control, a large number of resources are wasted under conventional fermentation conditions, but new molecules are difficult to obtain, and production and smooth follow-up biological activity research are not facilitated are effectively solved. The invention provides the preparation method and the application of the novel bird nest alkane diterpenoid compound.

A method for identifying biomarkers indicative of neurodegeneration using a covariance neural network (VNN) includes providing a VNN trained on brain anatomical data primarily composed of healthy subjects, making the largest proportion of the population in the data. Brain anatomical data of a subject is provided as input, and, based on the input, the VNN generates a set of biomarkers and a brain health marker indicative of neurodegeneration of the subject.

The invention provides a cyclic peptide used for treating, improving or preventing nervous system injury of mammals or diseases or pains caused by the injury, neurodegenerative diseases, anxiety or epilepsy or used as a neuronal protective agent, a conjugate containing the cyclic peptide, a pharmaceutical composition containing the cyclic peptide or the conjugate and application of the cyclic peptide and the conjugate.

The invention provides a novel light-sensitive channel protein VR2.0 and application thereof. The photosensitive channel protein VR2.0 series provided by the invention has an obvious treatment effect in treatment of retina photoreceptor cell degenerative diseases. The novel light-sensitive channel protein has higher light sensitivity, fast dynamics and low side effect; under the same light stimulation condition, the response frequency is fast, and stable current signals can be kept under high frequency response. The application provides a better choice for developing photogenetic therapy for retina photoreceptor cell degenerative diseases, and has important application and popularization values.

The invention relates to a nasal administration preparation of a multi-target drug and application of the nasal administration preparation. The nasal administration preparation of the multi-target medicine is prepared by dissolving or suspending the compound shown in the formula I or the chiral enantiomer or the pharmaceutically acceptable salt thereof in a solvent. The nasal administration preparation can smoothly reach the brain after nasal administration, and high exposure in the brain is achieved, so that the in-vivo effect of the nasal administration preparation for treating neurodegenerative diseases is improved. # imgabs0 #

The invention discloses application of LW6 in preparation of drugs for preventing and treating neuroinflammation and protecting microglial cells. Cell experiments prove that the LW6 can inhibit the expression of HIF-1alpha protein in LPS-induced microglial cells BV2, can inhibit the mRNA expression level of inflammatory factors IL-1beta and IL-6 in the microglial cells BV2, and can inhibit the mRNA expression level of microglial cell inflammatory enzyme iNOS, which indicates that the LW6 can protect the microglial cells and prevent and treat neuroinflammation, and has a significant effect on degenerative diseases such as Alzheimer's disease. The compound has certain significance in treating Parkinson's disease, and can be used for preparing medicines for preventing and treating neuroinflammation and medicines for protecting microglial cells.

The invention belongs to the field of antibodies, and particularly relates to a p-Tau217 phosphorylated protein binding antibody or an antigen binding part thereof and application thereof. The invention provides the amino acid sequences of the heavy chain CDR and the light chain CDR of the antibody specifically bound with the p-Tau217 phosphorylated protein, and the antibody can specifically recognize and bind the p-Tau217 phosphorylated protein and has the advantages of high affinity and good specificity to the protein. Based on the advantages, the antibody can be applied to diagnosis of diseases (such as nervous system degenerative diseases) related to abnormal p-Tau217 phosphorylated protein level, and especially can be applied to clinical diagnosis of Alzheimer's disease.

The present invention relates to novel body tissue radiofrequency applicators (50), referred to as BTRFAs, as well as to a non-invasive medical head device useful for stabilizing and / or reversing the symptoms of neurodegenerative diseases and / or proteinopathies. The novel BTRFAs and medical head device are particularly useful for stabilizing and / or reversing the symptoms of Alzheimer's disease and / or Parkinson disease in a subject in need thereof.

The invention belongs to the technical field of traditional Chinese medicine biology, and particularly relates to a phenolic diastereoisomer and a preparation method and application thereof.The phenolic diastereoisomer has the chemical structural formula shown in the formula I and the formula II, the formula I is dextroisomer and is named as (+)-fresh bamboo juice phenol D, and the formula II is levoisomer and is named as (-)-fresh bamboo juice phenol D. A pair of phenolic diastereoisomer compounds (+)-fresh bamboo juice phenol D and (-)-fresh bamboo juice phenol D are successfully obtained from fresh bamboo juice, and an anti-neurotoxicity activity test shows that (+)-fresh bamboo juice phenol D has a remarkable protection effect on PC12 cell injury caused by glutamic acid and can be used for preparing medicines for preventing or treating neurodegenerative diseases; wide application prospects are realized.

The invention provides a compound with a new structure as an LRRK2 inhibitor, and a stereoisomer, an optical isomer and a medicinal salt thereof. And a new direction is provided for the development of LRRK2 inhibitor drugs. In-vitro enzyme and cell activity inhibition activity researches show that the compounds have strong inhibition effects, and can be used as promising compounds for treating and / or preventing LRRK2-mediated diseases (such as nervous system degenerative diseases, especially Parkinson's disease).

The present application discloses different classes of mitochondrial uncoupling compounds having significantly improved pharmacokinetic properties and conventional mitochondrial uncoupling compounds, pharmaceutical compositions containing the compounds and / or prodrugs, and diseases that are useful in the treatment of diseases associated with mitochondrial dysfunction or benefits by modulation of mitochondrial activity. Methods of using the compounds, prodrugs, and pharmaceutical compositions in treatment of diseases, including diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), mitochondrial genetic diseases, neurodegenerative diseases, cancer, autoimmune diseases, and infectious diseases.

The present disclosure relates to an imidazole lipid and a use thereof. Specifically, provided are a compound represented by formula I or a salt thereof, and a lipid particle or a pharmaceutical composition containing the compound. The compound can be used as a delivery system, and is used for preparing drugs for preventing and / or treating cancers, infectious diseases, autoimmune diseases, neurodegenerative diseases, inflammation, etc. The definition of each group in formula (I) is as described in the description.

One aspect of the present disclosure is a composition for preventing or treating a retinal degenerative disease, capable of preventing or delaying retinal cell degeneration. The composition for preventing or treating a retinal degenerative disease, in one aspect, contains exosomes extracted from human-derived mesenchymal stem cells as an active ingredient.

The present application relates to a diacetylene compound represented by formula (I), or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and a use of the compound, the pharmaceutically acceptable salt thereof, and the pharmaceutical composition. The compound, or the pharmaceutically acceptable salt thereof and the pharmaceutical composition comprising same can be used for preparing a drug for treating or relieving neuroinflammation and neurodegenerative diseases.

The invention discloses a fluorescent / photoacoustic dual-mode diagnosis and treatment probe for detection and photodynamic removal of senescent cells, a preparation method and application, the probe takes a sulfur-substituted hemicyanine dye as a parent structure, a novel bromo-glycoside ligand is covalently coupled, and a blue-green solid is obtained after gradient purification. The probe system shows a remarkable optical response characteristic on beta-galactosidase (beta-Gal) and ideal singlet oxygen (1O2) generation efficiency; an optical signal and a photodynamic therapy effect of the probe can be specifically activated by beta-galactosidase (beta-Gal) overexpressed in cancerous cells and senescent cells under a light excitation condition; the result is successfully verified in a palbociclib-induced senescence melanoma model. According to the probe disclosed by the invention, collaborative regulation and control of dual-mode visual monitoring and precise photodynamic therapy of beta-Gal enzyme activity are realized for the first time, a novel tool is provided for researching a molecular mechanism of cell aging and developing a diagnosis and treatment strategy of aging-related diseases, and the probe has a remarkable application value in the fields of anti-tumor treatment and degenerative diseases.

The present invention relates to a method of differentiating an induced pluripotent stem cell into a retinal pigment epithelial cell. Additionally, the present invention relates to a retinal pigment epithelial cell culture obtainable by the differentiation method and a retinal pigment epithelial cell culture obtained by the differentiation method. In addition, the present invention concerns a retinal pigment epithelium consisting of or comprising a retinal pigment epithelial cell culture obtainable or obtained by the differentiation method. The present invention also relates to a pharmaceutical composition comprising a retinal pigment epithelial cell culture obtained by the differentiation method. The present invention concerns a method of treating a retinal degenerative disease in a subject, comprising administering to a subject a retinal pigment epithelial cell differentiated from the induced pluripotent stem cell by the method. Finally, the present invention also refers to an in vivo method of detecting the survival rate of a retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in a subject and an in vitro method of determining the immunogenicity of said retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in said subject, to whom said differentiated RPE cell has been pre-delivered.